AMRN

Peers: ARWR IONS OGN NAMS RDY CRDL LXRX ANIP KNSA AMRX

Index	-
Market Cap	244.57M
Enterprise Value	-65.03M
Income	-27.07M
Sales	185.85M
Book/sh	21.12
Cash/sh	14.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	80
IPO	Apr 01, 1993

P/E	-
Forward P/E	-
PEG	-
P/S	1.32
P/B	0.55
P/C	0.78
P/FCF	15.73
EV/EBITDA	-
EV/Sales	-0.35
Quick Ratio	2.67
Current Ratio	3.67
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.30
EPS next Y	-0.34
EPS next Q	-0.10
EPS this Y	-565.48%
EPS next Y	42.55%
EPS next 5Y	-
EPS past 3/5Y	29.16% -14.55%
Sales past 3/5Y	-16.59% -19.12%
EPS Y/Y TTM	74.20%
Sales Y/Y TTM	-15.63%
EPS Q/Q	46.70%
Sales Q/Q	-42.58%
Earnings	Jul 29 BMO
EPS/Sales Surpr.	-100.00% -5.25%

Insider Own	0.02%
Insider Trans	0.00%
Inst Own	20.00%
Inst Trans	0.04%
ROA	-4.18%
ROE	-5.96%
ROIC	-6.03%
Gross Margin	40.42%
Oper. Margin	-12.88%
Profit Margin	-14.57%
SMA20	-5.75%
SMA50	-12.91%
SMA200	-19.73%
Trades

Shs Outstand	21.12M
Shs Float	21.12M
Short Float	2.50%
Short Ratio	7.89
Short Interest	0.53M
52W High	20.90 -44.59%
52W Low	11.25 2.93%
Volatility	2.81% 2.86%
ATR (14)	0.37
RSI (14)	28.08
Beta	0.82
Rel Volume	0.36
Avg Volume	66.93K
Volume	21,786

Perf Week	0.00%
Perf Month	-14.09%
Perf Quarter	-15.54%
Perf Half Y	-20.19%
Perf YTD	-17.02%
Perf Year	-42.81%
Perf 3Y	-23.29%
Perf 5Y	-88.49%
Perf 10Y	-81.68%
Recom	5.00
Target Price	12.50
Prev Close	11.53
Price	11.58
Change %	0.43%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-21-26	Resumed	JP Morgan	Underweight	$13
Nov-20-23	Resumed	JP Morgan	Underweight
Oct-25-23	Downgrade	Jefferies	Buy → Hold	$3 → $1
Jan-06-23	Upgrade	Jefferies	Hold → Buy	$1.30 → $3
May-06-22	Downgrade	JP Morgan	Neutral → Underweight
May-05-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10 → $3
May-05-22	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $3
May-04-22	Downgrade	Northland Capital	Outperform → Market Perform
May-12-21	Downgrade	Goldman	Neutral → Sell	$6 → $5
Sep-29-20	Resumed	JP Morgan	Neutral
Aug-26-20	Initiated	Piper Sandler	Overweight	$21
May-05-20	Initiated	Northland Capital	Outperform	$15
Mar-31-20	Upgrade	Oppenheimer	Underperform → Perform
Mar-31-20	Downgrade	Jefferies	Buy → Hold	$30 → $4
Mar-31-20	Downgrade	Goldman	Buy → Neutral
Mar-13-20	Upgrade	Goldman	Neutral → Buy	$28
Mar-02-20	Initiated	Cowen	Outperform	$23
Feb-18-20	Upgrade	Citigroup	Neutral → Buy	$27 → $24
Jan-06-20	Initiated	JP Morgan	Neutral	$22
Dec-16-19	Downgrade	Stifel	Buy → Hold

Show Previous Ratings

Sep-11-26 11:36AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Quartz)
Aug-31-26 08:15AM	Amarin Highlights New REDUCE-IT and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026 (GlobeNewswire)
Aug-28-26 08:15AM	New REDUCE-IT Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients (GlobeNewswire)
Aug-24-26 10:10AM	Amarin to Present New REDUCE-IT and EPA Analyses at ESC Congress 2026 (InvestorsHub)
08:15AM	New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026 (GlobeNewswire)
03:03PM	Loading…
Jul-29-26 03:03PM	Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges (GuruFocus.com)
10:42AM	Amarin Reports Second-Quarter Results as Partnered International Strategy Gains Momentum (InvestorsHub)
07:27AM	Amarin: Q2 Earnings Snapshot (Associated Press)
07:00AM	Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence (GlobeNewswire)
Jul-15-26 08:00AM	Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 (GlobeNewswire)
Jun-30-26 04:15PM	Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape (GlobeNewswire)
Jun-05-26 07:51AM	Generic drugmakers gain key victory in skinny label patent case (BioPharma Dive)
May-27-26 11:24AM	Amarin Highlights New REDUCE-IT Analysis Showing Risk-Weighted ApoB May Improve Cardiovascular Risk Detection (AMRN) (InvestorsHub)
08:00AM	New REDUCE-IT Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia (GlobeNewswire)
Apr-30-26 03:05AM	Amarin Corp PLC (AMRN) Q1 2026 Earnings Call Highlights: Revenue Growth and Market Expansion ... (GuruFocus.com)
10:19AM	Loading…
Apr-29-26 10:19AM	Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy (InvestorsHub)
08:48AM	Amarin: Q1 Earnings Snapshot (Associated Press)
07:00AM	Amarin Reports 2026 First Quarter Financial Results (GlobeNewswire)
Apr-15-26 08:00AM	Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 (GlobeNewswire)
Apr-08-26 08:00AM	American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction (GlobeNewswire)
Mar-18-26 08:30AM	Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline (GlobeNewswire)
Mar-16-26 08:15AM	New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo (GlobeNewswire)
Mar-05-26 08:24AM	AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know (Zacks)
Mar-02-26 08:00AM	Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT Post Hoc Analysis Published in the European Journal of Preventive Cardiology (GlobeNewswire)
Feb-26-26 09:21AM	Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss (Zacks)
Feb-25-26 02:03PM	Amarin Corp PLC (AMRN) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines with ... (GuruFocus.com) -9.47%
11:02AM	Amarin Q4 Earnings Call Highlights (MarketBeat)
07:32AM	Amarin: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-23-26 08:00AM	This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease (GlobeNewswire)
08:00AM	Loading…
Feb-11-26 08:00AM	Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 (GlobeNewswire)
Jan-28-26 05:39AM	New Strong Sell Stocks for January 28th (Zacks)
Jan-22-26 10:28AM	BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? (Zacks) +7.98%
Jan-20-26 08:34AM	Do Options Traders Know Something About Amarin Stock We Don't? (Zacks)
Jan-10-26 02:57PM	Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights (Insider Monkey)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
07:00AM	Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization (GlobeNewswire)
Jan-08-26 07:00AM	Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities (GlobeNewswire) +16.89%
Dec-03-25 11:30AM	Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report? (Zacks)
Nov-09-25 04:15PM	New REDUCE-IT Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA/VAZKEPA (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients (GlobeNewswire)
Nov-03-25 08:30AM	Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 03:34PM	Amarin Corp PLC (AMRN) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 07:29AM	Amarin: Q3 Earnings Snapshot (Associated Press Finance) -11.25%
07:00AM	Amarin Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-28-25 09:57AM	Earnings To Watch: Amarin Corp PLC (AMRN) Reports Q3 2025 Results (GuruFocus.com)
Oct-27-25 08:00AM	Amarin Issues Statement Supporting FDA's Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit (GlobeNewswire)
Oct-23-25 10:06AM	Do Options Traders Know Something About Amarin Stock We Don't? (Zacks)
Oct-20-25 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
Oct-15-25 08:00AM	Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT and EPA Mechanistic Data at the Canadian Cardiovascular Congress (GlobeNewswire)
Oct-06-25 09:41AM	Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Sep-26-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Sep-03-25 11:30AM	Prothena (PRTA) Up 17.6% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-31-25 08:30AM	Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025 (GlobeNewswire)
Aug-30-25 08:30AM	New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups (GlobeNewswire)
Aug-25-25 08:00AM	New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025 (GlobeNewswire)
Aug-22-25 09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
Aug-14-25 11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-06-25 09:40AM	Is Amarin (AMRN) Outperforming Other Medical Stocks This Year? (Zacks)
Jul-31-25 10:37AM	Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises (Zacks)
Jul-30-25 07:05AM	Amarin: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Amarin Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-29-25 05:19PM	Recordati 1H Net Rev Climbs 12% to 1.3 Bln on Rare Diseases Unit Strength (Exec Edge)
12:13PM	RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES IN THE FIRST HALF OF 2025 REVENUE +11.7%, EBITDA(1) +9.6%, ADJUSTED NET INCOME(2) +8.9% (GlobeNewswire)
10:00AM	What To Expect From Amarin Corp PLC (AMRN) Q2 2025 Earnings (GuruFocus.com)
Jul-24-25 12:10PM	Amarin Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
10:45AM	VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales (Zacks)
Jul-23-25 07:30AM	Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025 (GlobeNewswire)
Jul-21-25 09:40AM	Are Medical Stocks Lagging DexCom (DXCM) This Year? (Zacks)
Jul-18-25 09:25AM	Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin (Zacks)
Jul-17-25 03:00PM	3 Strong Buy Breakout Stocks for Explosive Returns (Zacks)
Jul-14-25 09:06AM	Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus (Zacks)
Jul-11-25 12:12PM	FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill (Zacks)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks)
Jul-09-25 12:26PM	PROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy Study (Zacks)
Jul-02-25 09:40AM	Are Medical Stocks Lagging Amarin (AMRN) This Year? (Zacks)
Jul-01-25 09:17AM	Moderna Stock Gains on Encouraging Flu Vaccine Data (Zacks)
Jun-27-25 10:00AM	Best Momentum Stock to Buy for June 27th (Zacks)
Jun-25-25 11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
09:28AM	Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-24-25 07:05AM	RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE (GlobeNewswire) +27.26%
07:00AM	Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA (Icosapent Ethyl) in Europe (GlobeNewswire)
Jun-23-25 12:34PM	SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma (Zacks)
Jun-20-25 09:46AM	Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid (Zacks) -5.93%
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-16-25 09:55AM	Amarin (AMRN) Now Trades Above Golden Cross: Time to Buy? (Zacks)
09:40AM	Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-10-25 12:00PM	Amarin (AMRN) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
10:00AM	Best Momentum Stocks to Buy for June 10th (Zacks)
09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks)
06:50AM	New Strong Buy Stocks for June 10th (Zacks)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +7.34%
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks)

Show Previous News

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

CEOMr. Aaron D. Berg

Senior VP & CFOMr. Peter L. Fishman

Executive VP & Chief Operating OfficerDr. David Keenan Ph.D.

Executive VPDr. Steven B. Ketchum Ph.D.

Executive VPMr. Jonathan N. Provoost

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Amarin Corp ADR

Upgrade your Finviz experience